Target intelligence / Profile preview

Cellular retinoic acid-binding protein 2 (CRABP2) (CRABP2)

Target
CRABP2
Molecular classification
Intracellular lipid-binding protein, Retinoic acid carrier, Transcription cofactor
01

Overview

Cellular retinoic acid-binding protein 2 (CRABP2) is a small intracellular protein that serves as a high-affinity carrier for all-trans-retinoic acid (atRA) (UniProt P29373). It plays a critical role in the retinoic acid signaling pathway by shuttling atRA from the cytoplasm into the nucleus upon ligand binding. Once in the nucleus, CRABP2 physically interacts with the Retinoic Acid Receptor (RAR) through a specific delivery interface, facilitating the direct channeling of atRA into the receptor's ligand-binding pocket (Budhu & Noy, 2002). This mechanism significantly enhances RAR-mediated transcriptional activity, which governs cell differentiation and growth arrest. In clinical contexts, CRABP2 is often viewed as a tumor suppressor in breast cancer, where its presence sensitizes cells to the anti-proliferative effects of retinoids (Schug et al., 2007). Conversely, its absence or a shift in the CRABP2/FABP5 ratio can lead to retinoid resistance or the activation of alternative survival pathways. Understanding the CRABP2-RAR interface is therefore vital for developing strategies to overcome drug resistance in retinoid-based therapies.

Other names
CRABP-IICellular retinoic acid-binding protein IIRBP6Retinoic acid-binding protein II
02

Mechanism of action

CRABP2 facilitates the direct transfer of all-trans-retinoic acid (atRA) to the Retinoic Acid Receptor (RAR) by forming a transient protein-protein complex at the delivery interface, a process known as ligand channeling that ensures efficient activation of RAR-mediated transcription (Budhu & Noy, 2002; Dong et al., 1999).

03

Biological functions

Retinoic acid transportNuclear translocationLigand channelingRegulation of gene expressionCell differentiationApoptosis induction
04

Disease associations

CancerBreast cancerPancreatic cancerSkin disordersAcute promyelocytic leukemia
05

Safety considerations

TeratogenicityRetinoid resistanceMucocutaneous toxicityHypertriglyceridemia
06

Interacting drugs

Tretinoin

5 more in the full profile.

07

Biomarkers

CRABP2 protein expressionCRABP2 mRNA levelsCRABP2/FABP5 expression ratio

Beyond the preview

Go deeper on Cellular retinoic acid-binding protein 2 (CRABP2) (CRABP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular retinoic acid-binding protein 2 (CRABP2) (CRABP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call